Abstract
Drug repurposing is an attractive and pragmatic way offering reduced risks and development time in the complicated process of drug discovery. In the past, drug repurposing has been largely accidental and serendipitous. The most successful examples so far have not involved a systematic approach. Nowadays, remarkable advances in drugs, diseases and bioinformatic knowledge are offering great opportunities for designing novel drug repurposing approach through comprehensive understanding of drug information. In this study, we introduced a novel drug repurposing approach based on transcriptomic data and chemical structures using deep learning. One strong candidate for repurposing has been identified. Pimozide is an anti-dyskinesia agent that is used for the suppression of motor and phonic tics in patients with Tourette’s Disorder. However, our pipeline proposed it as a strong candidate for treating non-small cell lung cancer. The cytotoxicity of pimozide against A549 cell lines has been validated.
Highlights
The knowledge and technology of human diseases have developed substantially, the translation of these benefits into therapeutic innovations has been far slower than expected [1, 2]
This paper aimed at providing a novel drug repurposing approach to discover alternative non-small cell lung cancer (NSCLC) drugs from existing drugs
Misclassified antineoplastic drugs are compared with Food & Drug Administration (FDA) approved NSCLC drugs
Summary
The knowledge and technology of human diseases have developed substantially, the translation of these benefits into therapeutic innovations has been far slower than expected [1, 2]. The main challenges facing global pharmaceutical industries are substantial costs and long consuming time in the process of drug discovery and development [2]. To solve this problem, drug repurposing ( known as drug repositioning, re-tasking or reprofiling) has emerged as an attractive and pragmatic way offering reduced risks and development time [3]. The boom of drugs, diseases and bioinformatic knowledge is offering great opportunities for designing novel drug repurposing approach [4,5,6,7,8]
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
